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Abstract 
Systemic lupus erythematous (SLE) is a chronic autoimmune disease characterised 
by multisystem involvement and a relapsing remitting course. SLE is a highly 
heterogeneous condition, with wide variations in both the presentation and severity 
of disease and the biological markers identified.  
The use of biologics in SLE has lagged behind that of other rheumatological 
conditions such as rheumatoid arthritis, in part due to the diverse clinical 
manifestations of SLE, making it difficult to design appropriate trials for novel 
treatments. As such, broad immunosuppressive treatment regimens are still widely 
used in SLE. Nevertheless, in recent years, elucidation of some aspects of SLE 
pathogenesis have allowed the development of therapies targeted at molecular 
mediators of SLE. This review provides an update of biological available therapies 
and those currently under development.   
Systemic lupus erythematous (SLE) is a chronic autoimmune disease characterised 
by its relapsing remitting course and multisystem involvement.  
The overall prevalence of SLE varies by ethnicity, age, geographical location and 
other factors. The prevalence in the United states has been quoted at between 14.6 
and 50 per 100,000 persons [1]. More recently, a retrospective study covering most 
of the French population has demonstrated a prevalence of 40.6 per 100,000 
persons [2].  
Clinical manifestations include constitutional symptoms, such as fever and malaise, 
in addition to dermatological, musculoskeletal, renal, respiratory, cardiovascular, 
haematological and neurological involvement [3,4]. 
The mainstay of treatment for SLE still relies heavily on glucocorticoids, antimalarials 
and immunosuppressive agents [5]. These treatments have led to vast 
improvements in the prognosis of SLE, despite presenting their own unique 
challenges due to numerous adverse effects. Disease refractory to conventional 
therapies as well as the challenges posed by immunosuppressive and cytotoxic 
treatments has led to the need for development of more efficacious interventions 
with fewer associated risks. 
The biological therapies represent a large group of emerging therapies for 
autoimmune diseases including SLE. However, both study design and identifying 
suitable and accurately measurable outcome criteria have presented significant 
barriers in the assessment of both efficacy and safety profiles in these promising 
new agents [6]. 
Here we discuss the current B-cell targeted therapies (Rituximab and Belimumab) 
already being used in the treatment of SLE, as well as the emerging treatments 
thought to act on a variety of specific immunological targets shown to play a role in 
the pathogenesis of SLE. 
B cell therapies already available  
Rituximab 
CD20 (or B-lymphocyte antigen CD20) is a protein widely expressed on B cell 
lymphocytes. Its function is as yet unknown. It is thought that it may play a role in 
calcium influx leading to the activation of B-cells. Rituximab is a chimeric monoclonal 
antibody against CD20 receptor. When rituximab binds CD20 it results in an 
asymmetric clustering of proteins on one side of the B-cell. This change in 
morphology leads to an increase in the successful kill rate by natural killer (NK) cells 
[7]. By this mechanism it is thought that rituximab results in a reduction in B-cell 
numbers and antibody titres. It is this purported mechanism of action that has, for 
years, underpinned the clinical use of rituximab in conditions where excess clonal 
proliferation of B-cells leads to an abundance of offending antibodies.  
Evidence from a number of open-label, uncontrolled studies has supported the use 
of rituximab in SLE for more than one decade [6]. More recently the randomised 
controlled trials (RCTs) EXPLORER (the exploratory Phase II/III SLE evaluation of 
rituximab) [8] and LUNAR (lupus nephritis assessment with rituximab) [9] 
investigated the use of Rituximab in patients with SLE. The results of these two 
RCTs showed no superiority when compared with conventional treatments. This 
having been said, a thorough critical evaluation of the trials’ design and observations 
is necessary before condemning the use of Rituximab in SLE altogether.  
Firstly, It has been suggested that patients included in both trials (particularly 
EXLPLORER) were likely to have less severe disease: in detail, in the EXPLORER 
trial,  previous cyclophosphamide (CYC) or high dose glucocorticoid therapy were 
among the exclusion criteria and in the LUNAR trial patients were included only if 
they experienced their first episode of lupus nephritis and were excluded if they had 
more than 50% glomerular sclerosis, interstitial fibrosis or an estimated glomerular 
filtration rate of <25ml/min/1.73m2 [10].  
Secondly, when looking at concomitant therapies used, both trials have been 
criticised for their use of high dose glucocorticoids (up to 1mg/kg) alongside 
Rituximab which many argue may have masked the true efficacy of B-cell depletion 
therapy in a short term follow-up period  [11]. 
Thirdly, when comparing Rituximab to Belimumab (an inhibitor of B lymphocyte 
stimulator, shown to be effective in SLE by the BLISS -52 and BLISS-76 trials) the 
numbers of patients enrolled in the EXPLORER and LUNAR trials were  smaller (257 
and 144, respectively) when compared to the trials which demonstrated Belimumab’s 
superior efficacy (867 in BLISS-52 and 819 in BLISS-76). 
Finally, and most critically, aiming to prove the superiority of rituximab over current 
first-line immunosuppressive therapies in SLE does not reflect the use of rituximab in 
clinical practice, where rituximab is mainly considered in refractory cases to these 
therapies. Herewith, a brief summary of real-life experiences supporting the 
beneficial use of Rituximab in selected cases.  
In Italy a multi-centre study looked at data from the off-label use of rituximab in the 
treatment of refractory lupus. They found a significant proportion of patients with a 
systemic complete response (CR) (defined as European Consensus Lupus Activity 
Measurement (ECLAM) score ≤1) or partial response (PR) (defined as 1< ECLAM 
≤3). Renal CR (RCR) and renal PR (RPR) were defined according to EULAR 
recommendations for management of lupus nephritis. Following rituximab use, CR or 
PR were observed in 85.8% and CR in 45.5% of cases, after 12-month follow-up 
[12].  
Ramos-Casals et al. reported 188 cases of refractory SLE treated with Rituximab in 
the literature. Of these 91% showed significant improvement in one or more systemic 
manifestations of SLE. When focusing on specific manifestation, it is worth noting 
that more than a hundred of the patients they reviewed had lupus nephritis and 91% 
of these achieved a response to treatment with rituximab [13]. Similarly, they found 
that non-renal manifestations of SLE showed improvement with rituximab. Notably 
they found that cardiopulmonary, haematological, articular and central nervous 
system manifestations of SLE showed a treatment response in 100%, 94%, 91% and 
89% of patients respectively. [13]  
Condon et al. followed 50 patients with biopsy proven (class III, IV or V) Lupus 
Nephritis treated with a regimen of three pulses of methylprednisolone (500mg) two  
rituximab infusions(1000mg), 14 days apart, given in combination with long term 
mycophenolate mofetil and in most cases without oral corticosteroids. Fourty-five 
patients (90%) had either a complete or partial response to treatment and of those 
45 only 2 patients required courses of oral steroids for a duration longer than 2 
weeks for acute flares of systemic disease.[14] Given that steroid burden in patients 
with lupus is a serious problem, this study presents an early insight into the possible 
benefits of a treatment regime that could dramatically reduce total corticosteroid 
doses. 
Davies et al. used rituximab to treat 18 patients with lupus nephritis refractory to 
conventional immunosuppressive therapy (including intravenous cyclophosphamide). 
Over the follow-up period (minimum 1 year and in some cases longer ) 13 out of 18 
patients achieved a (complete or partial) response following treatment with rituximab. 
However, this study also identified a poor response in patients with rapidly 
progressive crescenteric lupus nephritis with existing evidence of significant renal 
impairment. In these patients rituximab did not prevent progression to end-stage 
renal failure and dialysis [15].  
Cobo-Ibáñez et al [16]. performed a systematic review of the efficacy and safety of 
rituximab in non-renal SLE. From a literature search they identified 26 studies (1 
randomized controlled trial and its exploratory analysis, 2 open-label studies and 22 
cohort studies, of which 15 were prospective), which in total analysed 1231 patients 
with SLE refractory to glucocorticoids and/or immunosuppressant drugs. They 
concluded from their analyses that rituximab could be considered a safe and 
effective short-term treatment in non-renal SLE, reducing disease activity, steroid 
doses and anti-ds-DNA levels and increasing complement levels. They did however 
identify significant relapses, with 11 studies reporting relapses in disease activity. 
The best responses to treatment were seen in articular involvement (complete or 
partial response ranging from 72% to 81.5% over 3-6 months) and 
thrombocytopaenia (of 6 cohort studies that evaluated short-term 
thrombocytopaenia, 3 showed 50–92% complete or partial response, and in the 
others the mean platelets level increase was significant). Regarding other non-renal 
manifestations the authors felt unable to draw meaningful conclusions due to lack of 
data.  
In Korea a multicentre retrospective analysis of the use of rituximab in refractory SLE 
demonstrated a global response to treatment in 28 of 39 patients. This was 
demonstrated by a significant reduction in SLEDAI scores over 6, 12 and 24 months 
after rituximab therapy. [17]  
Very recently, a promising role of rituximab in an intensified protocol of induction 
therapy has been reported in patients for whom avoiding immunosuppressive 
maintenance therapy and sparing steroids are particularly appealing [18]. Such 
different approach, initially employed as a rescue therapy in refractory LN, has been 
proposed in order to minimize the long-term effects of both corticosteroids and the 
immunosuppressive agents used for remission maintenance. It was based on an 
intensified B-lymphocyte depletion consisting of “four (weekly) plus two (monthly) 
doses” of rituximab (375 mg/sm), associated with two i.v administrations of 10 mg/ 
kg cyclophosphamide and three pulses of methylprednisolone, followed by oral 
prednisone tapered to 5 mg/day in 10 weeks, without further immunosuppressive 
maintenance therapy.  
Taken the above together, it is apparent that the conclusions arrived at by the 
EXPLORER and LUNAR trials differ from those presented by non-randomized 
studies and systematic reviews. There is a definite need for further large studies 
looking at the use of rituximab in patients with refractory SLE with both renal and 
non-renal manifestations. It seems however, that clinicians will continue to use 
rituximab in the treatment of refractory SLE. 
Belimumab 
B-lymphocyte stimulator (BLys) is a glycoprotein based cytokine and a member of 
the tumour necrosis factor (TNF) family, and is an important factor in controlling B 
cell survival and the generation of a normal immune response (Schneider et al 
1999). Transgenic mice over expressing BLys has been shown to develop 
autoimmune conditions analogous to SLE and Sjogren's syndrome in humans 
[19,20]. Indeed, levels of soluble BLys have been found of correlate to SLE disease 
activity in patients, both in terms of dsDNA levels and SELENA-SLEDAI scores [21].  
As such, developing an antagonist to BLys seems a logical step in the search for 
novel SLE treatments.  
Belimumab, a fully humanised monoclonal antibody inhibitor of BLys, gained 
regulatory approval in the US in 2011 and subsequently in Europe. As of writing, 
Belimumab remains the only licenced SLE biologic and US based studies carried in 
the last 2 years estimated that 5%-6% of patients are currently being treated with this 
medication [22][23] 
Phase I and II trials for Belimumab were  carried out in 2008 and 2009, with cohorts 
of 72 and 449 patients respectively. These trials showed that administration of 
Belimumab  resulted in significantly reduced circulating CD20+ B cells levels after 4-
8 weeks (Furie et al., 2008, Wallace et al., 2009), thus providing a level of evidence 
for its molecular efficacy in humans. These two trials also provided evidence for the 
safety of Belimumab with similar numbers of adverse events (such as serious 
infections) in the treatment group compared to the placebo group.  
Potential confounders, which could have obscured an otherwise significant 
difference within a more specific group, included the heterogeneous patient 
population. The inclusion criteria was relatively broad, for example, while patients 
were required to have a history of positive circulating auto-antibodies, these 
antibodies did not have to be present at time of screening/initiation of therapy. The 
range of existing treatments for the trial cohort was also relatively diverse. In 
addition, Belimumab was used in combination with standard SLE therapies, changes 
in these standard therapies during the study could have masked/extenuated the 
effect that Belimumab would have otherwise had.  
Subcategory analysis showed that Belimumab was able to significantly reduce the 
number of disease flares during week 24-52, therefore suggesting that while 
suppression of B cell levels are achieved relatively early on in the treatment cycle, 
the clinical efficacy of Belimumab may take some time to take effect. Furthermore, 
subgroup analysis showed that seroactive patients (patients with clinically elevated 
circulating autoantibodies at the start of the trial, which was found to be correlated to 
BLyS levels) showed a significant greater reduction in SELENA-SLEDAI score 
compared to placebo. In addition, it was also noted that treatment with Belimumab 
reduced the required dose of corticosteroids in patients.  
Two multi-centre Phase III trials for Belimumab were conducted in 2011 (Bliss 52 
and 76), with over 1600 patients in total. Together, these two trials provided a good 
demographic coverage of the global SLE population (with the significant exception of 
Africa), with Bliss-52 being conducted in Asia, South America, and Eastern Europe 
and Bliss-76 carried out in the US and Europe [24,25]. Building on data from earlier 
studies, Belimumab was given with standard SLE therapy and compared with 
placebo plus standard SLE therapy. While a similar dose range of Belimumab was 
used (1 mg/kg and 10 mg/kg), higher disease activity was required in order to be 
included in these trials (a SELENA–SLEDAI score of ≥6 was needed compared to ≥4 
in phase II trials) , and the endpoint at which primary efficacy was measured was set 
at week 52 instead of week 24 
Both studies showed significant improvements in the SLE Responder Index (SRI) at 
the primary endpoint compared to placebo, with similar rates of adverse events. In 
the BLISS52 trial, both 1 mg/kg and 10 mg/kg doses of Belimumab produced a 
significant SRI rates (51% and 58% respectively) compared to placebo (SRI: 44%), 
while in the BLISS76 trial a significant effects was only seen with the higher 10 
mg/kg dose, where the SRI response of 42% compared to 33% in the placebo group. 
In both studies, the 10 mg/kg dose showed greater efficacy compared to the 1 mg/kg 
dose.  
In addition to dampening disease activity, Belimumab was also shown to decrease 
the risk of SLE flares (van Vollenhoven et al., 2012). Further analysis of the trial data 
showed that patients with low complement levels, higher SELENA–SLEDAI scores 
(>=10), positive dsDNA titres or those treated corticosteroids exhibited greater 
response to Belimumab compared to patients who lacked these features [26]. As the 
presence of the above features is correlated with more active disease, it can be 
inferred that Belimumab exhibits the greatest efficacy in patients with more severe 
SLE.  
In the BLISS 76 trial, SRI were also measured over a longer 76 week period. 
However, while SRI response rates was greater at this time point in the cohort 
treated with Belimumab compared to the placebo group, the improvement was not 
statistically significant [24]. The authors suggested that more liberal use of 
prednisolone in the placebo group coupled with a 7% dropout rate between weeks 
52 and 76 could have prevented the results from reaching significance. 
Nevertheless, these results does raise questions regarding the efficacy of prolonged 
use of Belimumab in patients with SLE.  
Taken the above together, some considerations are still needed. While in these 
studies, all patients received standard SLE therapy in addition to either placebo or  
Belimumab, a restriction of new immunosuppressive therapies during the trials was 
placed on the initiation. In addition, there were limits placed on the doses of existing 
immunosuppressive, antimalarial and corticosteroid agents used in patients in both 
groups for the duration of the trial. While these limits and prohibitions does most 
likely serve to create a less biased comparison to the fixed dose regimes of 
Belimumab in the trial group, it does remove some of the dynamic, real world clinical 
responses to the evolution of disease in patients from the field of comparison.  Use 
of IV Cyclophosphamide, historically regarded as a preferred treatment of severe 
SLE, was also an exclusion criteria in these studies [4]. Exclusion of such a major 
SLE treatment from comparison, whilst perhaps useful and necessary for the 
conduct of the trial, does also limit the potential application of the study’s results. 
In addition to cyclophosphamide, other major exclusion criteria in these studies were 
paediatric patients (age <18), and those with severe active central nervous system 
disease or/and severe active lupus nephritis, as such the usefulness of Belimumab 
in these patient populations cannot be extrapolated from these studies. A post hoc 
analysis of 267 patients with non-acute renal disease in these trials showed that 
Belimumab was more efficacious than placebo in terms of improving renal outcomes, 
however, statistical significance were not reached for many of the parameters 
measured. This inconclusive result is perhaps due to the relatively small numbers of 
renal patients involved and the fact that the BLISS trials excluded a significant 
proportion of patients with renal involvement [27].   
 
Upcoming biological agents targeting B cells 
Atacicept 
As described earlier in this article, both APRIL and Blys are secreted cytokines, 
produced by a variety of cells involved in immune mediation such as monocytes, 
dendritic cells, macrophages, and T cells. These factors then bind to B cell surface 
receptors and resulting in B cell maturation into plasma cells and APRIL has also 
been shown to enhance antigen presentation by B cells through binding to the B-cell 
maturation antigen [28,29].  Blys and APRIL levels are increased in patients with 
autoimmune disorders including SLE [30–32].  
Atacicept is a humanised recombinant protein, containing both human IgG and the 
extracellular portion of the B cell calcium-modulating ligand interactor (TACI), a 
receptor to which both Blys and APRIL bind in order to mediate their actions. 
Atacicept, with its binding site mimic, acts to bind Blys and APRIL, thereby blocking 
this signalling pathway [30,33][34].   
However, there does exist conflicting evidence where serum levels of APRIL was 
shown to be inversely correlated to both dsDNA titres and clinical disease activity in 
at least one study [35].  While, this study does not claim any causative link between 
any decrease in APRIL and flare of SLE, it does raise the question of whether Blys is 
a better inhibitory target for controlling the disease.  
In animal models of SLE, Atacicept was shown to reduce both B cell numbers and 
circulating Ig levels, and was able to delay the development of proteinuria and 
increase survival time in autoimmune-prone lupus mice [36,37].   
Results of a phase 1a trial, conducted with healthy male volunteers and using 
subcutaneous injections showed that Atacicept was well tolerated across a relatively 
wide dose range [38].  Results from two phase 1b trials showed that Atacicept 
administration was effective in reducing both B cell numbers and Ig levels in patients 
with SELENA–SLEDAI scores between 1 to 10. Major exclusion criteria in the two 
above studies study were patients already on immunosuppressive medications 
within 8 weeks of enrolment (i.e. azathioprine, methotrexate, mycophenolate, and 
cyclophosphamide), and patients on prednisolone doses greater than 20 mg. 
Furthermore, patients with significant neurological/CNS, liver, renal disease or 
congestive cardiac failure were also excluded [39,40]. These criteria limit any 
inferences regarding efficacy of Atacicept to SLE patients with mild or moderate 
disease without any significant major organ involvement.  
In subsequent years, two phase II/III trials were conducted for Atacicept [30,41]. The 
results from these trials, while showing clinical efficacy at higher doses compared to 
placebo, revealed concerns about the propensity of SLE patient having a higher 
probability of developing serious infections while on Atacicept.  
In the trial conducted by Isenberg et al, patients were randomised to receive placebo 
or Atacicept at 75 mg or 150 mg subcutaneously over a total of 52 weeks. At the 75 
mg dose, the investigators failed to show a significant improvement in either SLE 
flare rates or time to first flare compared to placebo. Unfortunately, two cases of fatal 
respiratory tract infections led to the early termination of the 150 mg arm. In addition, 
non-fatal infections were more common in the treatment group than the placebo 
group.  This outcome differs from the phase I trials where Atacicept appeared to be 
well tolerated. One explanation for this disparity could be that in the earlier trials 
Atacicept was either administered as a single dose or weekly for a maximum of 4 
weeks, whereas in the phase II/III trial treatment was continued for 52 weeks 
resulting in an increased period of more pronounced immunosuppression [30,39,40].   
However, despite the early termination, post-hoc analysis did show that at the 150 
mg dose, Atacicept was able to significantly decrease both flare rates (odds ratio 
0.48) and time to first flare (odds ratio 0.56). These results, while encouraging, need 
to be set against the risk for Atacicept to increase the chance of serious infections, 
especially in patients with only mild to moderate disease.  
A study published in 2012 showed an association in levels of serum APRIL and 
proteinuria and histological severity/activity in patients with lupus nephritis. 
Additionally, both serum APRIL and intrarenal mRNA of APRIL levels were 
correlated with increased resistance to treatment [41].  On the back of this data, a 
phase II/III trial was conducted to evaluate the efficacy of Atacicept in combination 
with corticosteroids and MMF in patients with active lupus nephritis [41].  The study 
was terminated after enrolling just 6 patients, due to the occurrence of serious 
adverse events. A significant reduction in serum Ig levels in the treatment group 
compared to the placebo group was observed on day 1 of treatment, and Ig levels 
continued to decline throughout treatment, in three cases reaching the 
discontinuation limit of < 3g/l. Two of these patients developed pneumonia. Patients 
in the treatment group also developed more pronounced proteinuria compared to 
placebo. It is possible that the combination of medication led to a greater level of 
immunosuppression than the investigators anticipated.  
The above studies raises serious concerns regarding the use of Atacicept in SLE 
patients and further studies are needed in order to assess its safety and 
pharmacodynamics before clinical efficacy can be evaluated. Evidence from trials on 
patients with rheumatoid arthritis also advices caution with a greater frequency of 
adverse events due to infections in the treatment cohort compared to those on 
placebo [42,43].   
Blisibimod 
Following from the success of Belimumab other Blys antagonists were developed. 
Blisibimod is a synthetic “peptibody” molecule where the stabilising effects of an Ig 
Fc fragment is used to reduce the rate of degradation of the pharmacologically active 
peptide [44]. It is able to bind both the membrane bond and soluble forms of Blys, 
which may allow it to achieve more potent level of target inhibition compared to 
Belimumab, which only binds soluble Blys [32].  
A placebo controlled phase I trial, where patients with either stable or inactive SLE 
wascarried out. Patients were given variable doses of Blisibimod in either a single 
injection or four weekly doses and the results compared to placebo. The percentage 
of adverse events between those treated with of Blisibimod and placebo were 
similar. Administration with of Blisibimod resulted in a significant reduction in the 
levels of naïve B cells, with a comparable increase in the number of memory B cells. 
However, by 160 days post administration the level of memory B cells had returned 
to baseline, while naïve B cell numbers continued to be supressed. This led to a total 
reduction in B cell numbers of around 30% [32].  
Building on the above data, a phase II trial was conducted on patients with moderate 
and severe SLE with a SELENA-SLEDAI score ≥6 and showed promising results 
[45].  Administration of Blisibimod resulted in significant reductions in dsDNA levels 
and B cell numbers coupled with increased C3 and C4 levels. At the highest doses, 
Blisibimod was able to significantly improve SLE Responder Index-5 response rates 
measured at week 20 post treatment (p=0.02). SRI response rates was the highest 
in patients with more severe disease (SELENA-SLEDAI ≥10) and receiving 
corticosteroid treatment at enrolment with 41.7% of patients achieving a ≥7 or ≥6=8 
point decrease in their SELENA-SLEDAI score. Furthermore, significant reductions 
in proteinuria was seen in patients with a protein creatinine ratio of 1-6 [46].  
A phase III doubled blinded placebo controlled trial was initiated in 2013 by with an 
enrolment target of around 400 patients. Included patients were those with active 
SLE with a SELENA-SLEDAI score of ≥10 despite on-going stable corticosteroid 
therapy. Either Blisibimod or placebo was administered alongside standard therapy. 
The primary endpoint was set as the proportion of patients achieving SLE 
Responder Index at week 52. It was announced that the study had recently reached 
its enrolment target with the study completion date set at December 2015 [47].   
Tabalumab 
The monoclonal antibody Tabalumab has a similar mechanism of action as 
Blisibimod, acting as an antagonist to both the membrane bound and soluble 
versions of BLys. As well as SLE, this medication has been trialled as a treatment for 
patients with rheumatoid arthritis with inadequate response to conventional 
treatments. The studies reported somewhat mixed results, with the most recent 
phase III trial failing to show clinical efficacy for Tabalumab. Nevertheless, the trials 
did show that Tabalumab was safe to use in RA patients  [48–52].   
More recently, two phase III trials have been conducted to assess the efficacy of 
Tabalumab [53,54].  In the ILLUMINATE-1 trial 1164 SLE patients with moderate to 
severe disease (SELENA-SLEDAI ≥6) were recruited. Standard of care therapy 
(SOC) was provided in addition to either Tabalumab (in the form of subcutaneous 
injections either two or four weeks’ ) or placebo. The study showed that SOC plus 
Tabalumab was effective in significantly reducing B cell levels, serum Ig and levels 
dsDNA, while increasing C3 and C4 titres compared to SOC plus placebo. However, 
the primary endpoint: (percentage of patients achieving SRI-5 at week 52), was not 
met, with a similar proportion of patients achieving SRI-5 in the two treatment groups 
(Fortnightly injections: 31.8%; 4 weekly injections: 35.2% and placebo: 29.3%), nor 
were the secondary endpoints met. Results from the ILLUMINATE-2 trial was more 
positive, the trial’s 1124 patients had similar disease characteristics as those in the 
ILLUMINATE-1 trial. With ILLUMINATE-2, the primary endpoint (SRI-5 at 52 weeks) 
was met with the more frequent fortnightly treatments (Treatment: 38.4% and 
placebo: 27.7% p=0.002). The results from the once monthly treatments narrowly 
missed reaching significance (34.8%, p=0.051). In addition, secondary endpoints, 
such as reductions in time to next severe flare and sparing of corticosteroids were 
not met. It is noted that Tabalumab was more effective achieving the SRI-5 response 
in patients who were serologically active, and these patients showed greater 
improvement in SELENA-SLEDAI score, B cell, Ig and complement levels.  
Data from these two large trials paint a mixed picture and it would appear that 
Tabalumab, while able to target both soluble and insoluble forms of BLys, is in fact 
less effective at controlling SLE disease activity compared to Belimumab. However, 
several potential confounders does exist in the study design, in the ILLUMINATE-1 
study, investigators deemed any changes to patient’s dose of steroids as failing the 
trial, even if the steroid dose was decreased. Also, it was pointed out by one of the 
primary investigators, that the target was perhaps set too high and the high levels of 
immunosuppression the patients in the study were already on could prevent the 
primary endpoint from being reached [55].  
These points highlight the difficulty in designing a suitable large scale trial for the 
study of a multi-system disease such as SLE, where it is often very difficult to reduce 
or stop the existing treatments that the patients are on in order to make an entirely 
objective comparison. It would seem that careful trial design and careful patient 
selection is key for studies such as the ones highlighted above to produce 
meaningful results.  
Epratuzumab 
Initially developed to treat non-Hodgkin’s lymphoma, Epratuzumab is a fully 
humanised monoclonal antibody against the B cell surface receptor CD-22, (Wallace 
et al., 2013a).  CD-22 is a glycol-protein membrane receptor which controls B cell 
activation and migration, it is also involved in B cell receptor (BCR) inactivation. CD-
22 has been shown to be elevated in patients in patients with SLE and other auto-
immune conditions [56].  
In 2006, a small phase II open label trial was conducted on 14 patients with 
moderately active SLE (BILAG score 6 to 12), with 4 doses of Epratuzumab being 
given intravenously two weeks apart [57]. Patients were followed up at regular 
intervals for 6 months post treatment. Treatment with Epratuzumab was well 
tolerated and  results showed  an average decrease of 35% in B cell levels at week 
18 (Epratuzumab has a half-life of 23.9 days) and no significant changes in  T cells 
levels, immunoglobulins, or autoantibody levels were detected. All 14 patients 
showed a ≥50% reduction in their BILAG scores at least one time point during the 
study, while 13 patients still experienced reductions in their BILAG at week 18 [57].  
More, recently, the results of a small (a cohort of 20 patients with moderate-severe 
SLE despite standard therapy) 12 week, placebo controlled, phase 1-2 trial was 
published [58].  Epratuzumab was administered either weekly or fortnightly in a 4 
week initial dosing period to achieve a cumulative dose (cd) of 200 mg to 2400 mg 
per patient. Epratuzumab was found to have an average half-life of 13 days, and its 
administration caused a decrease in both B cell numbers and average B cell CD-22 
fluorescence intensity. Again, Epratuzumab was found to be well tolerated in SLE 
patients.  
Building on the above studies, a randomised, double blinded, placebo controlled trial 
were conducted [59].  The EMBLEM trial recruited a total of 227 patients with 
moderate to severe SLE. Like the Tsuru et al study, patients received 
weekly/fortnightly Epratuzumab injections in a 4 week dosing period to achieve a cd 
of 200 mg to 3600 mg (5 treatment groups). Primary outcome was measured using a 
composite endpoint British Isles Lupus Assessment Group (BILAG)-based 
Combined Lupus Assessment (BICLA) (see addendum for score breakdown). It was 
reported that all treatment groups achieved a higher response rate compared to 
placebo, although the cumulative  results failed to reach significance (P=0.148). 
Group specific analysis revealed that in the 2400 mg (cd) group, a significant 
treatment effect (OR=2.9 (1.2 to 7.1), nominal p=0.02).  
The ALLEVIATE I and II trials recruited 90 patients in total and compared SOC plus 
Epratuzumab [60] (at 360 mg/m2 n=42 or 720 mg/m2 n=11) with SOC plus placebo 
(n=37). In both studies, Epratuzumab was administered in 12 week cycles for up to 
48 weeks, giving a total of 10 doses. The primary endpoint was BILAG response at 
week 24 (all BILAG reduced by at least one grade e.g. from B to C/D and no new A 
and <2 new B scores). Recruitment started in 2005, however both trials were 
terminated early due to interruptions in the drug supply. As such the primary end 
point was assessed at 12, instead of 24 weeks. The available data from both RCTs 
were combined and analysed. It was found at week 12, responses were 44.1% for 
patients receiving the 360 mg/m2 and 20% for the 720 mg/m2 dose, while the 
response rate was 30% for the placebo group [61].  In terms of quality of life 
outcomes, both patient and physician global assessments of disease activity (PtGA 
and PGA) showed greater improvements in the treatment arms compared to those 
receiving placebo and this was sustained through the trial but did not reach statistical 
significance. In addition, use of Epratuzumab was shown to be partially steroid 
sparing. At week 24, the mean cumulative corticosteroid doses for the groups on 
Epratuzumab was 1051 mg (360 mg/m2 group p=0.034) and 1973 mg (for the 720 
mg/m2 group p=0.081) less than the placebo group respectively (Strand et al., 
2014).  
A theory has been put forward as to why the lower dose (360 mg/m2) of 
Epratuzumab showed more clinical efficacy than the higher dose (720 mg/m2). It has 
been reported that when serum concentrations of anti CD-22 antibodies are high, a 
process named trogocytosis, mediated by mononuclear cells, facilitates the removal 
of CD-22 molecules from the cell membranes, thereby allowing the cells to escape 
antibody targeting [62].   
Twenty-nine patients who participated in the ALLEVIATE trials in the US were 
enrolled into a follow-on trial (SL0006) to study the efficacy and safety of long term 
administration of Epratuzumab. Patients were given Epratuzumab in 12 week cycles 
for a median of 120 weeks. However, it should be noted that due to the interruption 
in medication supply, there was a median delay of 165 days between the patients 
completing the ALLEVIATE trial and starting the SL0006 extension trial. Despite the 
delay, patients in the SL006 trial were able to maintain the improvement in their 
BILAG scores gained during treatment under ALLEVIATE [60].   
Based on the promising data from the above Phase I and II trials, two phase III trials 
have been initiated (EMBODY I and II), both studies have been completed (June 
2015), the results from these studies are still pending[63]. However in July 2015 it 
was reported that although these trials did not identify any new safety concerns, they 
did fail to reach their primary endpoint for both dose  of Epratuzumab [64].  
Ocrelizumab 
Like rituximab, Ocrelizumab is a monoclonal anti-CD20 antibody, and a B cell 
depleting agent. It binds a slightly different, but overlapping epitope as rituximab. In 
vitro experiments have shown that Ocrelizumab has greater ability to induce 
antibody-dependent cell-mediated cytotoxicity and reduced complement-dependent 
cytotoxicity compared to rituximab. If these effects hold true in vivo, it should lead to 
greater efficacy and reduced frequency and severity of adverse reactions [65].   
With regards to rheumatological conditions, the safety and efficacy of Ocrelizumab 
were more extensively studied in rheumatoid arthritis patients than SLE. Elevated 
numbers of serious infections were reported in several trials, especially with higher 
doses of Ocrelizumab (500 mg) [66–68].   
The BEGIN trial was initiated to study the safety and efficacy of Ocrelizumab in 
patient with non-renal SLE. This study was terminated early, due to the impression 
that Ocrelizumab was unlikely to be efficacious in active SLE [69].  
The phase III (double blinded, placebo controlled randomised) BELONG trial studied 
patients with class III/IV lupus nephritis, with 381 patients recruited [70]. Patients 
were given either placebo, 400 mg or 1000 mg of Ocrelizumab, on day 1 and 15 of 
the trial, then every 16 weeks to maintain a state of B cell depletion. Administration 
of Ocrelizumab or placebo was accompanied by corticosteroid treatment plus either 
MMF or cyclophosphamide followed by azathioprine. The primary endpoint was the 
percentage of patients achieving total or partial remission from lupus nephritis at 48 
week of treatment. BELONG was terminated early due to an significant higher 
number of serious infections in the Ocrelizumab group (28.8 events per 100 patients 
for the 400 mg group and 25.1 events per 100 patients in the 1000 mg group) 
compared with placebo group (18.7 events per 100 patients). Of note, this imbalance 
only occurred in patients receiving Ocrelizumab and MMF, but not patients receiving 
Ocrelizumab with CYC followed by azathioprine, potentially suggesting that 
Ocrelizumab and MMF exerts a greater than expected synergistic 
immunosuppressive effect. 
The response rates for patients treated with Ocrelizumab were greater than the 
group treated with placebo.  
 
Biological agents targeting IL-6 
 
Tocilizumab 
Under the influence of IL-6, B lymphocytes differentiate into mature plasma cells and 
secrete antibodies. IL- 6 levels have been shown to be raised in human and murine 
lupus, and murine studies have shown a link between IL-6 blockade and decreased 
levels of ds-DNA antibodies[71]. 
Tocilizumab is a humanized monoclonal antibody against the interleukin-6 
receptor (IL-6R). In an open-label phase I dosage escalation study Illei et al. 
administered tocilizumab (2mg/kg, 4mg/kg or 8mg/kg once a week, every other 
week) to 16 patients (one of whom was removed from the study for neutropenia), 
with mild-moderate disease activity scores, for 12 weeks. They were then monitored 
for an additional 8 weeks. They observed a ≥4 point reduction in SELENA scores in 
8 of the 15 patients. In the 7 patient with arthritis at the outset of the study, all saw an 
improvement, in 4 of these patients their arthritis completely resolved. Anti-ds-DNA 
antibody titres decreased by a median of 47% in the 4mg/kg and 8mg/kg dosage 
groups with a 7.8% decrease in IgG levels and a significant decrease in the 
frequency of circulating plasma cells. The study did however identify a transient drop 
in neutrophil counts (38% and 56% respectively in the 4mg/kg and 8mg/kg groups) 
which resolved after cessation of treatment.[72] Before tocilizumab could be part of 
the routine strategies in SLE, further studies are warranted.  
 
Sirukumab 
Sirukumab is a human monoclonal antibody that binds with high affinity to human IL-
6. Szepietowski et al. administered 10mg/kg of Sirukumab or placebo to 15 patients 
(with a 2:1 ratio respectively) with SLE (with a SELENA-SELDAI scores of 5-12) in a 
randomized, double-blinded, dose escalation study. Adverse events occurred more 
often with sirukumab than placebo (90% vs 80%). Dose-independent reductions in 
white blood cell counts, neutrophil counts and platelet counts were observed with 
Sirukumab with minor elevations in total cholesterol also being observed. No 
clinically relevant changes in disease activity scores were identified between the 
sirukumab and placebo groups[73].  
 
Biological agents targeting type I interferons 
Type I interferons (IFN) are implicated in the pathogenesis of SLE [74–76].  It has 
been suggested that autoreactive T-cells which have escaped central tolerance 
promote the proliferation of autoreactive B cells and plasma cells and the formation 
of autoantibodies. One theory behind this is that dendritic cells proliferate, which 
promote the survival of autoreactive T-cells, may be upregulated by the over-
production of IFN-α in response to environmental factors such as viral infections, 
implicated in the pathogenesis of SLE and subsequent disease flares.  
 
Sifalimumab 
Sifalimumab is a human IgG1 monoclonal antibody to interferon-α. Phase 1 trials 
have demonstrated an acceptable safety profile and shown that Sifalimumab tended 
to reduce the number of disease flares [77–79]. A phase IIb randomized, double-
blinded, placebo-controlled study followed 431 patients with moderate to severe SLE 
given monthly doses of 200, 600 or 1200mg of Sifalimumab or placebo for 1 year. 
Patients treated with Sifalimumab demonstrated reduced SLE disease activity over 
multiple clinical measures including joint involvement and fatigue scores. 
Surprisingly, neither high ds-DNA titres nor low complement levels were found to 
normalise over the course of the study [76].  
 
Rontalizumab 
Rontalizumab is a human IgG1 monoclonal antibody targeting all known isoforms of 
human IFN-α. Its safety and efficacy in SLE was first demonstrated by McBride et al. 
in a phase I study of 60 patients with SLE in a dose escalation study [80]. 
Subsequently a phase II study of 238 patients by Kalunian et al. showed no overall 
difference in response rates (evaluated by SRI/BILAG) between treatment and 
placebo at 24 weeks. However, an exploratory analysis showed a reduction in flare 
rates and steroid burden in some patients with a low baseline interferon signature 
metric (ISM)) in the rontalizumab arms [81]. 
IFN-α kinoid 
IFN-α kinoid (IFN-K), a drug composed of inactivated IFN-α coupled to a carrier 
protein (keyhole limpet hemocyanin) has shown promising results in murine SLE 
studies [82]. Lauwerys et al. conducted a multi-centre, randomized, double-blind, 
placebo-controlled study of 28 mostly Caucasian women with mild to moderate SLE 
with a range in SLEDAI-2K scores between 4 and 10. Their results showed that IFN-
K was well tolerated, induced anti-IFN antibodies, and down-regulated IFN-induced 
genes in patients overexpressing IFN-inducible genes at baseline. They also 
demonstrated that the anti-IFN antibody response induced by IFN-K was associated 
with the recovery of serum complement C3 levels[83].  
 
Biological agents targeting T cell  
Edratide 
Edratide is a tolerogenic peptide based on the sequence of the first complementarity-
determinind (CDR1) regions of an anti-DNA monoclonal antibody (16/6 idiotype).The 
drug has shown promising results in preliminary studies demonstrating the down 
regulation of cytokines, apoptosis and IFN-α gene expression [84][34]. A phase II 
trial of 340 SLE patients with SLEDAI-2K of 6–12 receiving either edratide or placebo 
showed an acceptable safety profile and the drug was overall well tolerated. The 
study failed to meet the primary endpoints of  reduction in SLEDAI-2K and adjusted 
mean SLEDAI. However, the secondary endpoint of improved BILAG scores was 
met for the 0.5mg Edratide arm. A post hoc analyses also showed promising results 
[85]. 
Laquinimod 
Laquinimod has been originally investigated in the treatment of relapsing–remitting 
multiple sclerosis [86]. Laquinimod downregulates the proinflammatory cytokines (IL-
6, IL-12, IL-17, IL-23, and TNF-a) but increases the production of IL-10, exerting an 
immunomodulating effects on antigen presenting cells that direct T cells. 
 Jayne et al. conducted a 24 week phase IIa study where laquinimod or placebo (in 
combination with standard of care treatments) were given to 46 patients (2:1 ratio 
respectively) with active lupus nephritis. Preliminary results (REF only able to find 
abstract not fully published study) showed an improvement in renal function (as 
assessed by eGFR and proteinuria) as well as appearing to be well tolerated 
throughout the treatment groups [87]. 
 
Rigerimod/Lupuzor 
Rigerimod, also known as Lupuzor, a novel 21-mer peptide agent currently 
undergoing phase III trials. This peptide is derived from a heavily phosphorylated 
region of the U1-70K snRNP protein, a nuclear riboprotein and a spliceosome 
component [88]. Auto-antibodies against this protein has been found in SLE and 
mixed connective tissue diseases [89,90].  The Lupuzor peptide contains an in-vivo 
phosphorylation site at position Ser140 (position 10 in the peptide itself), and is 
recognised by CD4+ T cells and binds IgG produced by classic murine models of 
SLE (MRL/lpr and (NZBxNZW) F1 mice) [91–93].   
Although the exact mechanisms of action of Lupuzor is not completely  understood , 
it doesn’t seem to act as a immunosuppressant in the classical sense but rather as 
an immunomodulator, which modifies the sequence of cellular auto-immunological 
events that leads to SLE disease progression. The process of autophagy, which 
modulates the disassembly and recycling of cellular components, has been shown to 
be an important pathway by which cellular antigens are presented to CD4+ T cells, 
which can then lead to the development of autoimmunity [94].  In mouse models 
administration of Lupuzor has been shown to reduce autoreactive T-cell priming by 
these antigens through reduction of the autophagic flux and reducing the stability of 
MHC II complexes [95–97].  Reassuringly, the effects of Lupuzor seems to be 
restricted to autoimmune processes and does not alter the ability to respond to viral 
infections in mouse models [96] which, if borne out in human patients, gives it a clear 
advantage compared to  traditional “broad spectrum” immunosuppressive agents.  
The safety and efficacy of Lupuzor was assessed in 2008 in an open label phase IIa 
trial involving 20 patients with moderately active SLE. This trial showed that the 
peptide was well tolerated and that three administrations of Lupuzor at 200 µg 
resulted in significant reductions in both auto-antibody levels and physician assessed 
disease activity [98]. This trial was followed by a double blinded placebo controlled 
phase IIb trial involving 149 patients who scored ≥6 on the SLEDAI-2K. This trials 
showed that an injection of Lupuzor (200 µg) every 4 weeks  was efficacious  in  
61.9% of patients,  measured by the SLE Responder Index (SRI) compared to 
38.6% in the placebo group [99].  
A phase III trial is currently underway in the US and Europe and going through 
patient recruitment and ethics approval. [100] 
Biological Agents approved for other indication: the case of Abatacept  
To launch a T cell dependent B cell response, T cells require two distinct signals. 
The first specific pathway involves the binding of the T cell receptor (TCR) to antigen 
in the context of major histocompatibility complex class II. The second involves non-
antigen specific pathways. Of these pathways the best described are the receptor 
ligand interactions between CD28 and CTLA4 (a molecule homologous to CD28 only 
expressed on activated T cells) on T cells with B7 molecules expressed on antigen 
presenting cells. If a T cell receives the first signal but not the second it will become 
anergic or undergo apoptosis.  
Abatacept (a fusion protein composed of the Fc region of the immunoglobulin IgG1 
fused to the extracellular domain of CTLA-4) binds B7 and in doing so halts the 
second pathway leading to unsuccessful T cell activation thereby preventing the B 
cell response [101].  
In a phase IIb trial, Merrill et al. randomized 118 patients to receive abatacept and 57 
to receive placebo in conjunction with 30mg prednisolone per day, to be tapered 
after 1 month. On entry to the trial patients should have BILAG A or B on at least one 
system. They found that after the start of the steroid taper, and over 12 months, 
there was no significant difference in (BILAG A/B) flare rates between the abatacept 
and placebo groups, 79.7 and 82.5% respectively[102].  However, post hoc analyses 
revealed that severe flares (BILAG A) were less frequent in the abatacept compared 
to the placebo group (40.7 vs 54.4%, with a treatment difference of -13.7 [95% CI -
29.5, 2.1]) [103]  
Furie et al. conducted a 12 month randomised, phase II/III, double-blinded study of 
298 patients (with active class II or IV LN) treated with either abatacept (30mg/10kg 
or 10mg/10kg) or placebo on a background of MMF and corticosteroids. They used a 
composite end-point of ‘time to confirmed complete response’ demonstrated by 
maintenance of glomerular filtration rate, minimal proteinuria and inactive urinary 
sediment over the 12 month treatment period. They showed no differences among 
treatment arms in the primary end-point [104].  
Taken the above together, the use of Abatacept in SLE is still debatable and should 
be considered only in very selected case.  
 
Expert commentary  
Recent advances in SLE research have started to elucidate the complex 
pathogenesis underlying this autoimmune condition highlighting the critical role of 
auto-B cells in autoantibody formation, antigen presentation and T cell interaction. 
The approval of Belimumab by the FDA in 2011 was a significant milestone for the 
treatment of SLE. Promising preliminary results of ongoing studies such as those 
with epratuzumab and blisibimod further support the concept that targeting B-cell 
remains a promising approach in the treatment of SLE.  
However, response to B cell target therapy is still variable across studies. Upcoming 
synthetic peptides and new oral immunomodulator agents might also be effective in 
SLE treatment. Considering the successful application of small molecule-mediated 
inhibition in treating malignancies in hematology, the idea of providing a specific, 
tailored to the patient’s ‘molecular identity’ and possibly less toxic therapeutic agent 
in patients with SLE appears greatly attractive.  
However, it is important to remember that the variability of the disease might impact 
on clinical response among SLE patients. The  synergistic role of these new agents 
used with conventional drugs, the optimal dosages and duration of treatment have to 
be further investigated. With the availability of new agent growing, assessment tools 
have to be standardized and efficacy endpoints have to be appropriately defined. 
World-wide registry data collection and accurate post-marketing surveillance are also 
crucial to evaluate the long-term safety, efficacy, and cost-effectiveness of these 
novel therapies. 
5-year view 
The heterogeneous clinical presentation of SLE may pose the question that agents 
targeting B cells are not the ideal tool for treating all patients. Indeed, different 
clinical manifestations may underline slightly different pathophysiology pathways 
making B cells depletion/modulation ineffective in some patients but effective in 
others. Comparing the safety and efficacy profile of biologics targeting different 
molecular pathways in different patient subpopulations as well as in different SLE 
manifestations would help determine which biologics are most suited for certain 
types of patients and clinical manifestations. This would result in a more tailored 
approach in term of both clinical care and cost effectiveness.  
The principle of treating-to-target has been successfully applied in may rheumatic 
diseases, and above all in rheumatoid arthritis. The identification of tailored 
therapeutic goals and pursuing them in a systematic fashion has caused an  
improvement in the standard of care for patients with these conditions and useful 
guidance for healthcare practitioners and administrators. Very recently, a 
collaborative effort to identify possible therapeutic targets and design treat-to-target 
guidances in the management of SLE was attempted. To date, the treatment options 
for SLE consist of a relatively small number of agents in the therapeutic classes of 
glucocorticoids, anti-malarials, immunosuppressives and biologics. In the latter 
group, only Belimumab is approved for SLE, while Rituximab is used not infrequently 
‘off-label’ in refractory cases.  
The common goal of all of these agents is the control of disease activity and the 
reduction  flares rate, leading to a net minimization of long-term damage accrual in 
SLE patients. Indeed,  in the era of the omics,  it is crucial that important adjunctive 
therapies such as hydroxychloroquine and optimization of cardiovascular risk factors 
should not be forgotten in SLE management.  
Several new agents of significant interest are at different stage of development for 
the treatment of SLE, raising hopes that will soon be possible to aim for therapeutic 
targets with greater confidence that they can be succeeded.   
 
Key issues 
• Belimumab is the first agent licensed for use in SLE in more than fifty 
years. 
• Despite the poor outcome of two RTCs,  the use of Rituximab in 
refractory/life-threatening SLE is supported by open label and uncontrolled 
studies.  
• Cautious evaluation of the risk/benefit balance of upcoming molecules in 
SLE is essential.  
• Treat-to-target approach includes early management of lupus nephritis, 
minimizing exposure to corticosteroids, prevention of long-term damage 
accrual and improving quality of life in SLE patients 
• A better understanding of the pathogenic pathways along with their lupus-
relevant molecular aberrations may allow for more targeted and rational 
interventions  
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